Hospira Backs WHO's Proposed Biologicals Naming Plan -- But With Big Caveats

A key biosimilar developer, Hospira, supports the World Health Organization's biologic naming approach -- a qualifier attached to the nonproprietary name -- but with some big caveats, including that it should not be used for prescribing. Innovator drug makers support WHO's biological qualifier idea, according to recently released minutes from an April WHO meeting where stakeholders staked out positions on the idea before it was formally unveiled last month. The Generic Pharmaceutical Association is still reviewing the WHO proposal, but...